BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 17319473)

  • 1. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
    Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
    Farnier M; Chen E; Johnson-Levonas AO; McCrary Sisk C; Mitchel YB
    Vasc Health Risk Manag; 2014; 10():279-90. PubMed ID: 24855368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.
    Hu M; Yang YL; Ng CF; Lee CP; Lee VWY; Hanada H; Masuda D; Yamashita S; Tomlinson B
    Medicine (Baltimore); 2015 May; 94(20):e881. PubMed ID: 25997070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
    Savinova OV; Fillaus K; Harris WS; Shearer GC
    Atherosclerosis; 2015 Jun; 240(2):520-5. PubMed ID: 25932792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
    Moriarty PM; Roth EM; Karns A; Ye P; Zhao SP; Liao Y; Capuzzi DM; Bays HE; Zhang F; Liu S; Reichman AJ; Brusco OA; Lu G; Lerman S; Duan Z; Guo S; Liu PL; Zhao J; Zhang Y; Li S
    J Clin Lipidol; 2014; 8(6):568-575. PubMed ID: 25499939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
    Pan J; Van JT; Chan E; Kesala RL; Lin M; Charles MA
    Metabolism; 2002 Sep; 51(9):1120-7. PubMed ID: 12200755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
    Bays HE; McGovern ME
    Prev Cardiol; 2003; 6(4):179-88. PubMed ID: 14605511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
    Hunninghake DB; McGovern ME; Koren M; Brazg R; Murdock D; Weiss S; Pearson T
    Clin Cardiol; 2003 Mar; 26(3):112-8. PubMed ID: 12685616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin extended-release/lovastatin: combination therapy for lipid disorders.
    Moon YS; Kashyap ML
    Expert Opin Pharmacother; 2002 Dec; 3(12):1763-71. PubMed ID: 12472373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
    Kashyap ML; McGovern ME; Berra K; Guyton JR; Kwiterovich PO; Harper WL; Toth PD; Favrot LK; Kerzner B; Nash SD; Bays HE; Simmons PD
    Am J Cardiol; 2002 Mar; 89(6):672-8. PubMed ID: 11897208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.